During the past decade, ACRC Studies conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 7 clinical trials were completed, i.e. on average, 36.8% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 7 clinical trials were completed. i.e. 41.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ACRC Studies" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Pfizer" with 3 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored, "Biohaven Pharmaceuticals, Inc." with 2 trials sponsored and "Incyte Corporation" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ACRC Studies" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator and "Dermira, Inc." with 2 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "ACRC Studies" are "Atopic Dermatitis" (4 trials), "Systemic Lupus Erythematosus" (3 trials), "Ulcerative Colitis" (3 trials), "Heart Failure" (2 trials) and "Chronic Gout" (1 trials). Many other conditions were trialed in "ACRC Studies" in a lesser frequency.

Most popular intervention types in "ACRC Studies" are "Drug" (15 trials), "Biological" (4 trials), "Other" (4 trials), "Device" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Etrasimod" (4 trials), "Baricitinib" (3 trials), "Lebrikizumab" (2 trials) and "Vehicle" (2 trials). Other intervention names were less common.

The vast majority of trials in "ACRC Studies" are 20 trials for "All" genders.

Currently, there are NaN active trials in "ACRC Studies". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in ACRC Studies, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in ACRC Studies, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".